- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07949591
Foxtail Millet (Setaria Italica (L.) P. Beauv.)-Based Diet on Postprandial Glycemic Control in Adults With Obesity and Type 2 Diabetes
This 10-week randomized controlled trial evaluated the nutritional quality and dose-specific effects of foxtail millet muffins (50 and 100 g/day) alongside a low-glycemic index diet among 102 obese adults with T2DM. The study will assess changes in glycemic control, lipid profile, liver function, and anthropometric parameters to investigate the potential of foxtail millet as a functional dietary intervention for diabetes management.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
This 10-week randomized controlled trial investigated the nutritional quality and potential health benefits of foxtail millet (Setaria italica) muffins among 102 obese adults with type 2 diabetes mellitus (T2DM). Participants were randomly allocated into three groups: placebo (wheat muffin, T₀), low-dose foxtail millet muffin (50 g/day, T₁), and high-dose foxtail millet muffin (100 g/day, T₂), with all groups following a standardized low-glycemic index diet. The nutritional composition, including proximate constituents and mineral content, and sensory acceptability of the muffins were evaluated using standard AOAC procedures and a 9-point hedonic scale. Anthropometric measurements, including body weight, BMI, and other relevant parameters, were assessed alongside fasting blood glucose (FBG), glycated hemoglobin (HbA1c), lipid profile, and liver function biomarkers at baseline and after the intervention. The study aimed to determine whether daily consumption of foxtail millet-based muffins could provide a nutritionally valuable dietary option and support improvements in glycemic regulation, metabolic health, and anthropometric status among obese adults with T2DM.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: SANA NOREEN, PhD
- Telefonnummer: 03018661160
- E-post: SANA.NOREEN@DNSC.UOL.EDU.PK
Studiesteder
-
-
Punjab Province
-
Lahore, Punjab Province, Pakistan, 54000
- Sana Noreen
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- People between 30 to 60 years old.
- Body Mass Index (BMI) ≥30.0 kg/m².
- Fasting blood glucose levels ≥ 7.0 mmol/L (126 mg/dL).
- Individuals having HbA1c ≥ 6.5%.
- Elevated Lipid Profile: TC > 200 mg/dL, TG > 150 mg/dL, LDL-C > 100 mg/dL, HDL-C < 40 mg/dL (men) / < 50 mg/dL (women).
- Elevated Liver Function Tests: ALT > 56 U/L, AST > 40 U/L, ALP > 147 U/L, Total Bilirubin > 1.2 mg/dL, Albumin < 3.5 g/dL.
Exclusion Criteria:
- Individuals who have a known allergy or have experienced any adverse reaction to foxtail millet or any of the ingredients used in the muffins will not be included in the study.
- Patients who are taking medications known to significantly alter glucose metabolism or gastrointestinal absorption.
- Individuals who have recently had gastric surgery or who have surgery planned during the research period.
- Presence of other severe chronic diseases (e.g., severe renal, hepatic, or cardiovascular disease, active cancer).
- Nursing or pregnant females.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: PLACEBO T0
T₀; wheat muffin |
wheat muffin |
|
Eksperimentell: Intervention Group (T₁)
low-dose foxtail millet muffin (T₁; 50 g/day) |
low-dose foxtail millet muffin (T₁; 50 g/day) |
|
Eksperimentell: Intervention Group (T₂)
high-dose foxtail millet muffin (T₁; 100 g/day) |
high-dose foxtail millet muffin (T₂; 100 g/day) |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
bmi
Tidsramme: 10 weeks
|
Body mass index (BMI) was calculated as body weight (kg) divided by the square of height (m²) and expressed in kg/m². |
10 weeks
|
|
HBA1c
Tidsramme: 10 weeks
|
Glycated hemoglobin (HbA1c) was measured to assess average blood glucose levels over the preceding 2-3 months and expressed as a percentage (%). |
10 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
LIPID PROFILE
Tidsramme: 10 WEEKS
|
Lipid profile, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), was assessed and expressed in mg/dL. |
10 WEEKS
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- REC-UOL-/586/11/24
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .